MedElevator
Войти в исследования Journal of cardiovascular medicine (Hagerstown, Md.) · 2026
Inclisiran safety and efficacy in real-world clinical practice: results of a retrospective observational investigation.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Di Fusco Stefania Angela, Matteucci Andrea, Aiello Alessandro, Aquilani Stefano, Fedele Silvio, Nardi Federico, Colivicchi Furio
Аннотация
BACKGROUND: Real-world data on inclisiran are limited. We report a single-centre investigation on inclisiran safety and efficacy based on concurrent lipid-lowering treatments.
RESULTS: At 15 months, the mean low-density lipoprotein cholesterol (LDL-C) levels decreased by 59.5% in patients receiving statin ± ezetimibe and by 56% in those treated without statin ± ezetimibe (P < 0.001). Inclisiran with statin ± ezetimibe led to a higher likelihood of achieving LDL-C less than 55 mg/dl. Adverse effects (5.8%) were mild.
MAJOR FINDINGS: This real-world study confirms inclisiran as a well tolerated and potent LDL-C-lowering treatment, with a greater efficacy when used in association with statins ± ezetimibe.
RESULTS: At 15 months, the mean low-density lipoprotein cholesterol (LDL-C) levels decreased by 59.5% in patients receiving statin ± ezetimibe and by 56% in those treated without statin ± ezetimibe (P < 0.001). Inclisiran with statin ± ezetimibe led to a higher likelihood of achieving LDL-C less than 55 mg/dl. Adverse effects (5.8%) were mild.
MAJOR FINDINGS: This real-world study confirms inclisiran as a well tolerated and potent LDL-C-lowering treatment, with a greater efficacy when used in association with statins ± ezetimibe.